ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Generics

Sonorant debuts as Mallinckrodt spins off generics

by Rick Mullin
May 30, 2019 | APPEARED IN VOLUME 97, ISSUE 22

Mallinckrodt plans to spin off its specialty generics and active pharmaceutical ingredient (API) business to shareholders, creating two independent companies: Sonorant Therapeutics, focused on branded pharmaceuticals, and Mallinckrodt, focused on generics and APIs. Sonorant will retain the constipation drug Amitiza, which was originally to go with specialty generics. Mallinckrodt said in December that it was considering separating the generics business.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment